AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis

Oral Oncology

Volumn 46, Issue 7, 2010, Pages 564-570

  Caluwaerts, Silvia ^a   Vandenbroucke, Klaas ^a   Steidler, Lothar ^a   Neirynck, Sabine ^a   Vanhoenacker, Peter ^a   Corveleyn, Sam ^a   Watkins, Brynmor ^b   Sonis, Stephen ^c   Coulie, Bernard ^a   Rottiers, Pieter ^a  

^a ActoGeniX NV   (Belgium)

^b Biomodels   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Drug evaluation; Lactococcus lactis; Oral mucositis; Preclinical; Trefoil Factor

Indexed keywords

AG 013; MOUTHWASH; PROBIOTIC AGENT; TREFOIL PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG FORMULATION; DRUG SAFETY; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LACTOCOCCUS LACTIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; STOMATITIS;

ANIMALS; CRICETINAE; HUMANS; LACTOCOCCUS LACTIS; MOUTHWASHES; PEPTIDES; RATS; STOMATITIS; TREATMENT OUTCOME;

EID: 77953359952     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2010.04.008     Document Type: Article

References (20)

1. Vera-Llonch M., Oster G., Hagiwara M., and Sonis S. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer 106 2 (2006) 329-336 [January 15]
2. Kjellev S. The trefoil factor family - small peptides with multiple functionalities. Cell Mol Life Sci 66 8 (2009) 1350-1369 [April]
3. Taupin D., and Podolsky D.K. Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol 4 9 (2003) 721-732 [September]
4. Jagla W., Wiede A., Hinz M., et al. Secretion of TFF-peptides by human salivary glands. Cell Tissue Res 298 1 (1999) 161-166 [October]
5. Beck P.L., Wong J.F., Li Y., et al. Chemotherapy- and radiotherapy-induced intestinal damage is regulated by intestinal trefoil factor. Gastroenterology 126 3 (2004) 796-808 [March]
6. Peterson D.E., Barker N.P., Akhmadullina L.I., et al. Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. J Clin Oncol 27 26 (2009) 4333-4338 [September 10]
7. Rottiers P., De Smedt T., and Steidler L. Modulation of gut-associated lymphoid tissue functions with genetically modified Lactococcus lactis. Int Rev Immunol 28 6 (2009) 465-486
8. Cialdella J.I., Vavra J.J., and Marshall V.P. Susceptibility of bacteria to serum lysis or phagocytosis following growth in subinhibitory levels of lincosaminide or spectinomycin related antibiotics. J Antibiot (Tokyo) 39 7 (1986) 978-984 [July]
9. Rubenstein E.B., Peterson D.E., Schubert M., et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100 Suppl. 9 (2004) 2026-2046 [May 1]
10. Spielberger R., Stiff P., Bensinger W., et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351 25 (2004) 2590-2598 [December 16]
11. Perry JK, Kannan N, Grandison PM, Mitchell MD, Lobie PE. Are trefoil factors oncogenic? Trends Endocrinol Metab December 1, 2007.
12. Regalo G., Wright N.A., and Machado J.C. Trefoil factors: from ulceration to neoplasia. Cell Mol Life Sci 62 24 (2005) 2910-2915 [December]
13. Fujimoto J., Yasui W., Tahara H., et al. DNA hypermethylation at the pS2 promoter region is associated with early stage of stomach carcinogenesis. Cancer Lett 149 1-2 (2000) 125-134 [February 28]
14. Park W.S., Oh R.R., Park J.Y., et al. Somatic mutations of the trefoil factor family 1 gene in gastric cancer. Gastroenterology 119 3 (2000) 691-698 [September]
15. Lefebvre O., Chenard M.P., Masson R., et al. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 274 5285 (1996) 259-262 [October 11]
16. Tomasetto C., Wolf C., Rio M.C., et al. Breast cancer protein PS2 synthesis in mammary gland of transgenic mice and secretion into milk. Mol Endocrinol 3 10 (1989) 1579-1584 [October]
17. Playford R.J., Marchbank T., Goodlad R.A., Chinery R.A., Poulsom R., and Hanby A.M. Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. Proc Natl Acad Sci USA 93 5 (1996) 2137-2142 [March 5]
18. Steidler L., Neirynck S., Huyghebaert N., et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 21 (2003) 785-789
19. Sonis S.T., Peterson R.L., Edwards L.J., et al. Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol 36 4 (2000) 373-381 [July]
20. Sonis S.T. Pathobiology of mucositis. Semin Oncol Nurs 20 1 (2004) 11-15 [February]